The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | How do we treat GEJ carcinoma resistant to HER2 targeted therapies?
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on treatment strategies for patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma who are resistant to anti-HER2 based regimens such as trastuzumab with pembrolizumab. Resistance can occur due to mutations in the MAP kinase pathway or loss of HER2 expression. Patients with the former condition can receive second or third line anti-HER2 therapies such as trastuzumab deruxtecan. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
